Amneal Pharmaceuticals (AMRX) Set to Announce Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) is set to issue its quarterly earnings data before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The business had revenue of $616.98 million during the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ:AMRX opened at $5.90 on Friday. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. The company has a fifty day simple moving average of $5.72 and a 200 day simple moving average of $5.18. The firm has a market cap of $1.81 billion, a PE ratio of -19.03 and a beta of 1.33. Amneal Pharmaceuticals has a 12-month low of $1.64 and a 12-month high of $6.46.

Wall Street Analyst Weigh In

A number of equities analysts have commented on AMRX shares. The Goldman Sachs Group lifted their price objective on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a report on Monday, March 4th. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, January 29th. Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.